147 related articles for article (PubMed ID: 16798005)
1. Cromolyn administration (to block mast cell degranulation) reduces necrosis of dystrophic muscle in mdx mice.
Radley HG; Grounds MD
Neurobiol Dis; 2006 Aug; 23(2):387-97. PubMed ID: 16798005
[TBL] [Abstract][Full Text] [Related]
2. Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment.
Radley HG; Davies MJ; Grounds MD
Neuromuscul Disord; 2008 Mar; 18(3):227-38. PubMed ID: 18207402
[TBL] [Abstract][Full Text] [Related]
3. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice.
Hodgetts S; Radley H; Davies M; Grounds MD
Neuromuscul Disord; 2006 Oct; 16(9-10):591-602. PubMed ID: 16935507
[TBL] [Abstract][Full Text] [Related]
4. Disodium cromoglycate protects dystrophin-deficient muscle fibers from leakiness.
Marques MJ; Ventura Machado R; Minatel E; Santo Neto H
Muscle Nerve; 2008 Jan; 37(1):61-7. PubMed ID: 17724738
[TBL] [Abstract][Full Text] [Related]
5. Factors inducing mast cell accumulation in skeletal muscle.
Lefaucheur JP; Gjata B; Sebille A
Neuropathol Appl Neurobiol; 1996 Jun; 22(3):248-55. PubMed ID: 8804027
[TBL] [Abstract][Full Text] [Related]
6. Blockade of TNF in vivo using cV1q antibody reduces contractile dysfunction of skeletal muscle in response to eccentric exercise in dystrophic mdx and normal mice.
Piers AT; Lavin T; Radley-Crabb HG; Bakker AJ; Grounds MD; Pinniger GJ
Neuromuscul Disord; 2011 Feb; 21(2):132-41. PubMed ID: 21055937
[TBL] [Abstract][Full Text] [Related]
7. Implications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscle.
Grounds MD; Radley HG; Gebski BL; Bogoyevitch MA; Shavlakadze T
Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):846-51. PubMed ID: 18215180
[TBL] [Abstract][Full Text] [Related]
8. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice.
Messina S; Bitto A; Aguennouz M; Minutoli L; Monici MC; Altavilla D; Squadrito F; Vita G
Exp Neurol; 2006 Mar; 198(1):234-41. PubMed ID: 16410003
[TBL] [Abstract][Full Text] [Related]
9. Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice.
Schertzer JD; Ryall JG; Lynch GS
Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E499-505. PubMed ID: 16621899
[TBL] [Abstract][Full Text] [Related]
10. A single 30 min treadmill exercise session is suitable for 'proof-of concept studies' in adult mdx mice: a comparison of the early consequences of two different treadmill protocols.
Radley-Crabb H; Terrill J; Shavlakadze T; Tonkin J; Arthur P; Grounds M
Neuromuscul Disord; 2012 Feb; 22(2):170-82. PubMed ID: 21835619
[TBL] [Abstract][Full Text] [Related]
11. Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis.
Grounds MD; Torrisi J
FASEB J; 2004 Apr; 18(6):676-82. PubMed ID: 15054089
[TBL] [Abstract][Full Text] [Related]
12. Enhanced sensitivity of mdx mice to intramuscular injection of compound 48/80.
Granchelli JA; Hudecki MS; Pollina CM
Res Commun Chem Pathol Pharmacol; 1994 Jun; 84(3):351-62. PubMed ID: 7938907
[TBL] [Abstract][Full Text] [Related]
13. Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse.
Briguet A; Courdier-Fruh I; Foster M; Meier T; Magyar JP
Neuromuscul Disord; 2004 Oct; 14(10):675-82. PubMed ID: 15351425
[TBL] [Abstract][Full Text] [Related]
14. Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity.
Spencer MJ; Walsh CM; Dorshkind KA; Rodriguez EM; Tidball JG
J Clin Invest; 1997 Jun; 99(11):2745-51. PubMed ID: 9169505
[TBL] [Abstract][Full Text] [Related]
15. Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species.
Whitehead NP; Yeung EW; Allen DG
Clin Exp Pharmacol Physiol; 2006 Jul; 33(7):657-62. PubMed ID: 16789936
[TBL] [Abstract][Full Text] [Related]
16. Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice.
Shavlakadze T; White J; Hoh JF; Rosenthal N; Grounds MD
Mol Ther; 2004 Nov; 10(5):829-43. PubMed ID: 15509501
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of deltaCaMKII isoforms in skeletal muscle regeneration: Implications in dystrophic muscle disease.
Abraham ST; Shaw C
J Cell Biochem; 2006 Feb; 97(3):621-32. PubMed ID: 16215994
[TBL] [Abstract][Full Text] [Related]
18. Muscle genome-wide expression profiling during disease evolution in mdx mice.
Marotta M; Ruiz-Roig C; Sarria Y; Peiro JL; Nuñez F; Ceron J; Munell F; Roig-Quilis M
Physiol Genomics; 2009 Apr; 37(2):119-32. PubMed ID: 19223608
[TBL] [Abstract][Full Text] [Related]
19. Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout.
Golumbek PT; Keeling RM; Connolly AM
Neuromuscul Disord; 2007 May; 17(5):376-84. PubMed ID: 17452104
[TBL] [Abstract][Full Text] [Related]
20. T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse.
Farini A; Meregalli M; Belicchi M; Battistelli M; Parolini D; D'Antona G; Gavina M; Ottoboni L; Constantin G; Bottinelli R; Torrente Y
J Pathol; 2007 Oct; 213(2):229-38. PubMed ID: 17668421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
